Project Grant R01CA290013
Award Date
3/19/25
Completion Date
2/28/30
Dollars Obligated
$442K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Lebanon, NH 03756, USA
Similar Awards
This $622,329 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) is funding research at Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1i that can prevent metastasis and improve the efficacy of chemotherapy for triple-negative breast cancer (TNBC). The key research objectives include: 1) Formulating the PDZ1i inhibitor for clinical use and characterizing its immunomodulatory effects in suppressing...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer.
The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of a novel, wearable, non-invasive medical device for treating metastatic triple-negative breast cancer (TNBC). The total award amount is $211,125, spanning a project period from June 1, 2024 to May 31, 2026.
The project aims to advance a technology using induced electric field (IEF) therapy to hinder tumor growth and metastasis in TNBC, which...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a two-pronged approach to target triple-negative breast cancer (TNBC). The $403,686 award, effective June 1, 2024 through May 31, 2026, will enable researchers at Rutgers, The State University of New Jersey to:
Explore the use of a targeted hybrid vector called AAVP to deliver human tumor necrosis factor (TNF) to both TNBC tumor cells and associated...
This $460,977 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to identify novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to mobilize tumor-specific CD8+ T cells for immunotherapy against triple-negative breast cancer (TNBC).
The research, conducted by Health Research, Inc. at the Roswell Park Division, aims to: 1) identify candidate CNE peptide sequences generated by...
This federal Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is funding research to evaluate a small-molecule compound, USCYL01, as a means to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The $400,000 award, spanning February 2025 to January 2026, supports two key objectives: 1) Assessing the toxicity and pharmacokinetic properties of USCYL01, which...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $460,015 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center to investigate the role of the ATR-METTL3-BRCA1 axis in DNA damage repair and its implications for triple negative breast cancer (TNBC). The research aims to elucidate how the METTL3 protein, when phosphorylated by the ATR kinase, interacts with BRCA1 to...
The National Cancer Institute (NCI) awarded a $474,547 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to the Regents of the University of Michigan to conduct research on targeting metabolic vulnerabilities of triple negative breast cancer (TNBC) stem cells. The research aims to evaluate the efficacy of a potent NQO1-bioactivatable redox cycling compound, IB-DNQ, alone or in combination with SOD1 inhibition, in selectively targeting TNBC cancer stem-like...
The National Cancer Institute (NCI) awarded a $616,071 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). This 5-year grant, which commenced on February 24, 2025, supports research to advance therapeutic interventions for TNBC, an aggressive form of breast cancer that...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to conduct preclinical research on novel antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC).
The key objectives are to: 1) generate and evaluate the cell-killing efficacy of GPR56-targeted ADCs in TNBC cell lines; 2) assess the safety and efficacy...